Last updated September 9, 2026
Key finding
The primary patency rate at 12 months was significantly higher in the DCB group (83.3% [95% CI, 71.8% to 96.7%]) than in the control group (56.7% [95% CI, 41.2% to 78.0%])
This study compared paclitaxel-coated balloon angioplasty to conventional balloon angioplasty in patients with DLASO, finding significant improvements with the former.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Long-Term (1–5 y)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study compared paclitaxel-coated balloon angioplasty to conventional balloon angioplasty in patients with DLASO, finding significant improvements with the former.
These findings suggest that paclitaxel-coated balloon angioplasty could be a preferred treatment option for patients with DLASO, potentially leading to better long-term outcomes and improved quality of life. Clinicians may consider this approach to enhance patient care and treatment efficacy.
The study's sample size may limit the generalizability of the findings. The follow-up period was limited to 12 months, which may not capture long-term outcomes. Complication rates were similar, suggesting no significant safety advantage.
Published in
Publication details and source links for this paper.
Bolong Z, Ruoyu C, Hanchong L, Shaoyong T, Yangchun L. For patients with DLASO, paclitaxel-coated balloon angioplasty is superior to conventional balloon angioplasty. Diabetology & Metabolic Syndrome. 2026;18:92. doi:10.1186/s13098-026-02121-3
The primary patency rate at 12 months was 83.3% for the DCB group compared to 56.7% for the control group.
The mean increase in ABI was greater in the DCB group (0.31) compared to the control group (0.21).
The target lesion revascularization rate was 0% in the DCB group versus 3.33% in the control group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Conventional plain balloon angioplasty (POBA), Paclitaxel-coated balloon angioplasty and Ankle-brachial index (ABI), Clinical improvement (Rutherford classification), Primary patency rate at 12 months, and 2 more.
This study contributes evidence to
Primary intervention
Conventional plain balloon angioplasty (POBA)
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
0
Related topics
10
Evidence pairs
0
Related studies
Core evidence
The primary outcomes reported in this study.
Conventional plain balloon angioplasty (POBA) → Ankle-brachial index (ABI)
Conventional plain balloon angioplasty (POBA) → Ankle-brachial index (ABI)
Conventional plain balloon angioplasty (POBA) → Clinical improvement (Rutherford classification)
Conventional plain balloon angioplasty (POBA) → Clinical improvement (Rutherford classification)
Conventional plain balloon angioplasty (POBA) → Primary patency rate at 12 months
Conventional plain balloon angioplasty (POBA) → Primary patency rate at 12 months
Conventional plain balloon angioplasty (POBA) → Simple reaction time
Conventional plain balloon angioplasty (POBA) → Simple reaction time
Conventional plain balloon angioplasty (POBA) → Target lesion revascularization (TLR) rate at 12 months
Conventional plain balloon angioplasty (POBA) → Target lesion revascularization (TLR) rate at 12 months
Paclitaxel-coated balloon angioplasty → Ankle-brachial index (ABI)
Paclitaxel-coated balloon angioplasty → Ankle-brachial index (ABI)
Paclitaxel-coated balloon angioplasty → Clinical improvement (Rutherford classification)
Paclitaxel-coated balloon angioplasty → Clinical improvement (Rutherford classification)
Paclitaxel-coated balloon angioplasty → Primary patency rate at 12 months
Paclitaxel-coated balloon angioplasty → Primary patency rate at 12 months
Paclitaxel-coated balloon angioplasty → Simple reaction time
Paclitaxel-coated balloon angioplasty → Simple reaction time
Paclitaxel-coated balloon angioplasty → Target lesion revascularization (TLR) rate at 12 months
Paclitaxel-coated balloon angioplasty → Target lesion revascularization (TLR) rate at 12 months
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Conventional plain balloon angioplasty (POBA) and Left Ventricular Structure, Conventional plain balloon angioplasty (POBA) and Clinical improvement (Rutherford classification).
This study contributes to the evidence on the following intervention-outcome relationships.
Procedures
Curated evidence collections and hubs this study is part of.
All studies measuring Clinical improvement (Rutherford classification)
Measures Clinical improvement (Rutherford classification) as a key outcome.
All studies on Conventional plain balloon angioplasty (POBA)
Contributes to Conventional plain balloon angioplasty (POBA) evidence base.
All studies measuring Left Ventricular Structure
Measures Left Ventricular Structure as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Paclitaxel-coated balloon angioplasty appears to improve ankle-brachial index (ABI).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Ankle-brachial index (ABI)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Paclitaxel-coated balloon angioplasty appears to improve clinical improvement (rutherford classification).
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Clinical improvement (Rutherford classification)
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Paclitaxel-coated balloon angioplasty appears to improve primary patency rate at 12 months.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Primary patency rate at 12 months
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Paclitaxel-coated balloon angioplasty appears to improve target lesion revascularization (TLR) rate at 12 months.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Target lesion revascularization (TLR) rate at 12 months
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
